Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
11 nov. 2021 02h30 HE
|
Allarity Therapeutics A/S
Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant),...
NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021
05 nov. 2021 17h11 HE
|
Allarity Therapeutics A/S
Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am...
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq
05 nov. 2021 16h48 HE
|
Allarity Therapeutics A/S
An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the...
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate
23 sept. 2021 03h00 HE
|
Allarity Therapeutics A/S
Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for...
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress
16 sept. 2021 04h00 HE
|
Allarity Therapeutics A/S
Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm,...
Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3
15 sept. 2021 17h55 HE
|
Allarity Therapeutics A/S
Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press...
Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3
14 sept. 2021 17h06 HE
|
Allarity Therapeutics A/S
Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription ...
MINUTES OF EXTRAORDINARY GENERAL MEETING 2021
31 août 2021 15h19 HE
|
Allarity Therapeutics A/S
31 August 2021 ALLARITY THERAPEUTICS A/S On 31 August 2021 at 13:00 (CEST), an extraordinary general meeting of shareholders (the "General Meeting") of Allarity Therapeutics A/S, company...
Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021
26 août 2021 02h32 HE
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (August 26, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces that an accelerated extraordinary and final exercise period for warrants...
Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq
23 août 2021 02h45 HE
|
Allarity Therapeutics A/S
Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth quarter, 2021A previously-announced U.S. $20 million investment by 3i Fund supports Company’s transition to the...